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Abstract 
Human leukocyte antigen G (HLA-G) has multiple immune regulatory functions including the 
induction of immune tolerance in malignancies. The roles of HLA-G have not been investi-
gated in nasopharyngeal carcinoma (NPC). This study is aimed to evaluate the role of HLA-G 
as prognostic factor for NPC patients as well as its role in the immune regulation. Western 
assays showed high HLA-G expression in NPC cell lines, but low in the immortalized naso-
pharyngeal epithelial cell line NP69. HLA-G protein was further detected in 79.2% of 552 NPC 
specimens with immunohistochemistry (IHC), but not in normal nasopharyngeal epithelium 
tissue. Moreover, high expression of HLA-G predicted poor survival of NPC patients and 
positively correlated with tumor N classification and recurrence or metastasis. Multivariate 
analysis indicated that HLA-G was an independent and unfavorable prognostic factor. Fur-
thermore, the presence of CD68
+macrophages and IL-10 were also examined, which are two 
prognostic markers of NPC and important factors for regulating immune surveillance. The 
correlations of HLA-G with these two immune factors were revealed in NPC tissues. Taken 
together, our results suggest that HLA-G is an independent biomarker for NPC prognosis, 
and HLA-G might contribute to NPC progression, which might jointly regulate immune 
surveillance in NPC together with macrophages and IL-10. 
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Introduction 
Nasopharyngeal  carcinoma  (NPC)  is  a  leading 
lethal malignancy with a high prevalence in Southeast 
Asia, especially in the Guandong and Guangxi prov-
inces in Southern China [1-2]. Most NPC tumor cells 
are poorly differentiated or undifferentiated and have 
a high tendency to invade adjacent regions and me-
tastasize to neck lymph nodes. Although early-stage 
NPC is radio-curable, NPC patients at late-stage have 
poor outcomes, largely due to local failure in treat-
ments and distant metastases [3]. Conventional TNM 
staging  has  strong  prognostic  significance  for  NPC 
[4],  yet  the  prognosis  remains  poor  in  a  significant 
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number of NPC patients at late-stage [5]. Therefore, 
it’s  necessary  to  identify  additional  marker(s)  for 
predicting the clinical prognosis as well as serving as 
optimal therapeutic target(s) to benefit NPC patients. 
  Human    leukocyte    antigen    G    (HLA-G)    is    a   
non-classical    major    histocompatibility    complex   
(MHC)   class   Ib   antigen.   In non-pathological   situa-
tions,    HLA-G  expression    is    restricted    to    the    fe-
tal-maternal    interface    of    the    extravillous    cyto-
trophoblasts,    placental    chorionic    endothelium,   
thymic    epithelial    cells,    and    erythropoietic    lineage   
cells    from  the  bone  marrow  [6],  as    well    as    other   
immune-privileged    tissues    such    as    the    cornea  [7], 
  nail   matrix [8], and   autologous   tissues   such   as   the 
  pancreas [9]. It has been demonstrated that HLA-G 
plays  important  role  in  immune  tolerance  during 
pregnancy. It can suppress the proliferation of allore-
active CD4+ T-cell [10-12], block the effector function 
of decidual monocyte/macrophages [13], inhibit cy-
tolysis mediated by NK-cell and T cell [11, 14], mod-
ulate  the  release  of  cytokines  and  shift  decidual 
mononuclear cells toward the T helper (Th) 2 profile. 
Of  the  Th2  cytokines,  interleukin  (IL)-10  has  been 
shown to induce HLA-G expression, which in return 
stimulates  IL-10  expression  [15-17].  Interestingly, 
HLA-G expression was detected in various types of 
human  malignancies,  and    has  been  correlated  with 
certain clinicopathological parameters in gastric car-
cinoma [18], lymphoma [19-20], ovarian [21] and en-
dometrial  carcinoma  [22].  Moreover,  recent  studies 
have  suggested  that  HLA-G  may  promote  tumor 
progression  by  suppressing  immune  regulation 
within  tumor  microenvironment,  and  thus  helping 
tumor cells escape from anti-tumor immune surveil-
lance  [23].  Therefore,  these  studies  suggest  that 
HLA-G might serve as a clinical marker for the pre-
diction of clinical outcomes of these diseases [24-26].  
  Most  recently,  the  polymorphisms  of  HLA-G 
were associated with NPC risk and clinical outcome 
[27]. The Ile110 allele was  found  to be  signiﬁcantly 
less frequent among patients with a positive lymph 
node status and late stages (III–IV), respectively [27]; 
moreover,  the  occurrence  of  130C  deletion  was 
signiﬁcantly  associated  with  a  decreased  NPC  free 
disease and overall survival [27]. However, to date, 
the expression and role of HLA-G in NPC have not 
been investigated.  
Here, in order to explore the role of HLA-G in 
NPC, we first examined HLA-G expression in NPC 
using immunohistochemistry (IHC) and immunoblot 
(western)  methods;  and  secondly,  we  analyzed  the 
correlation between the HLA-G expression level and 
the clinical factors and outcomes of NPC patients; and 
finally, we evaluated the possible immune-regulatory 
function of HLA-G in the tumor microenvironment in 
NPC.  
Methods and Materials 
Patients and clinical tissue samples 
 In this study, 552 specimens of NPC were col-
lected  at  Sun  Yat-Sen  University  Cancer  Center, 
Guangzhou,  China  between  January  2001  and  De-
cember  2003.  The  cases  were  selected  based  on  the 
following criteria: pathologically confirmed NPC with 
available  biopsy  specimens  for  tissues  microarray 
(TMA) construction; no previous malignant disease or 
a  second  primary  tumor;  no  prior  radiotherapy, 
chemotherapy or surgery treatment history. All of the 
selected  NPC  samples  contained  at  least  70%  carci-
noma tissue, as determined by examining of the fro-
zen section. The characteristics  of the NPC  patients 
were summarized in Table 1.  
 
Table 1. Characteristics of nasopharyngeal carcinoma 
patients 
Characteristic  Nasopharyngeal carcinoma patients 
(N=552)% 
Sex   
  Female  134(24.3) 
  Male  418(75.7) 
Age (years)   
  Median(range)  46(19-78) 
  Mean+SD  46.78+11.065 
Clinical stage   
  Ⅰ-Ⅱ  147(26.6) 
  Ⅲ-Ⅳ  405(73.4) 
Progression   
  No  335(60.7) 
  Yes  217(39.3) 
Death   
  No  368(66.7) 
  Yes  184(33.3) 
Follow-up time (months)   
  Median(range)  67(2-99) 
  Mean+SD  58.63+1.097 
WHO histological classifi-
cation 
 
  NKUC  400(72.5) 
  NKDC  139(25.2) 
  KSCC  13(0.3) 
Note: SD, standard deviation; WHO, World Health Organization; 
NKUC, non-keratinizing undifferentiated carcinoma; NKDC, 
non-keratinizing differentiated carcinoma; KSCC, keratinizing 
squamous cell carcinoma. 
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All patients were treated with standard curative 
radiotherapy,  with  or  without  chemotherapy.  The 
follow-up period was defined as the time from diag-
nosis to the date of death or the lasted census date of 
living  patients.  Disease  progression  was  defined  as 
cases in which the tumor was evaluated as progres-
sive  disease  after  primary  treatment  or  recurrence 
(local progression) and/or cases in which new distant 
metastasis  occurred (distant progression). The Insti-
tute  Research  Medical  Ethics  Committee  of  Sun 
Yat-Sen University granted approval for this study. 
Tissue microarray construction 
The  paraffin-embedded  specimens  were  ob-
tained from the previously constructed tissue micro-
array (TMA) [28]. Briefly, the paraffin-embedded tis-
sue  blocks  and  the  corresponding  hematoxylin  and 
eosin  (H&E)  stained  slides  were  overlaid  for  TMA 
sampling.  Duplicates  of  1.0  mm  diameter  cylinders 
were  punched  from  representative  tumor  areas  of 
individual  tissue  block  and  re-embedded  into  a  re-
cipient  paraffin  block  at  a  defined  position  using  a 
tissue-arraying instrument (Beecher Instruments, Sil-
ver Spring, MD).  
Immunohistochemistry (IHC) and evaluation 
IHC was performed to examine HLA-G, CD68 
and IL-10 expression in NPC tissue  specimens.  Pri-
mary  antibodies  against  HLA-G  (1:200  dilution, 
sc-21799,  Santa  Cruz,  USA),  CD68  (1:100  dilution, 
ABIN370601, Dako, Denmark) and IL-10 (1:300 dilu-
tion, ab34843, Abcam, USA) were used in this study, 
following the previous protocol [28]. The IHC results 
were  evaluated  and  scored  independently  by  three 
pathologists without prior knowledge of the clinico-
pathological  outcomes  of  the  patients.  A 
semi-quantitative estimation was made using a com-
posite  score  obtained  by  adding  the  values  of  the 
staining intensity and the relative abundance of the 
positive cells. The intensity was graded as 0 (nega-
tive), 1 (weakly positive), 2 (moderately positive) or 3 
(strongly  positive).  The  abundance  of  the  positive 
cells was graded from 0 to 4 according to their per-
centages (0, < 5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; 4, 
76-100%). The concordance rate of 83.4% among the 
evaluated results from the pathologists demonstrated 
that this scoring method was highly reproducible. The 
value was selected until at least two pathologists re-
ported consistent results. In cases where scoring was 
completely  different,  all  of  the  pathologists  worked 
together to confirm the score. In addition, the num-
bers of CD68+ macrophages in tumor nest and stroma 
were counted within the areas of 6 high-power fields 
(400X). 
Selection of cutoff score 
Receiver  operating  characteristic  (ROC)  curve 
analysis was performed to determine the cutoff score 
for  a  “high  expression”  designation  with  the 
0,1-criterion implemented in SPSS software [28]. First, 
the  clinicopathologic  characteristics  were  dichoto-
mized  as  following  groups:  T  classification  (T1-T2 
versus  T3-T4),  N  classification  (N0  versus  N1-N3), 
clinical  stage  (I-II  versus  III-IV),  cancer  progression 
(Yes  versus  No),  and  survival  status  (death  due  to 
NPC versus censored). Second, the expression scores 
for  HLA-G  were  trained  in  the  ROC  analysis.  The 
cutoff score is the point on the curve that has both 
maximum sensitivity and specificity [28-29].  
Cell lines and cell culture 
Eight NPC cell lines including CNE2, S26, S18, 
SUNE1, 6-10B, 5-8F, CNE1 and HONE1 were cultured 
in RPMI 1640 (Gibco, USA) with 10% fetal bovine se-
rum (Gibco, USA). The NPC cell line C666 was cul-
tured in RPMI 1640 medium (Gibco, USA) containing 
15% FCS. The immortalized nasopharyngeal epitheli-
al  cell  line  NP69  was  cultured  in  keratinocyte  se-
rum-free medium (Invitrogen) supplemented with 5% 
FCS, 25 μg/ml bovine pituitary extract, and 0.2 ng/ml 
recombinant  epidermal  growth  factor,  as  suggested 
by the manufacturer. All the cell lines were grown in a 
humidified incubator at 37℃ with 5% CO2 .   
Immunoblot analysis 
Cells were harvested and lysed with RIPA buffer 
(Upstate, USA). Equal amount of denatured protein 
samples  were  separated  by  SDS-PAGE  and  then 
transferred to PVDF membranes (Amersham, UK) for 
immunoblot or western analysis. Antibodies used for 
immunoblot analysis were against HLA-G (same as 
the  one  used  in  IHC),  and  anti-α-tubulin  antibody 
(1:1,000 dilution, G436, Bioworld, USA) was used as 
loading  control.  All  protein  bands  were  visualized 
using an enhanced chemiluminescent western blot Kit 
(Amersham, UK). 
Statistical analysis 
Statistical  analysis  was  performed  using  SPSS 
(version 16.0; SPSS, Chicago, IL). ROC curve analysis 
was  applied  to  determine  the  cutoff  score  for  high 
expression  of  HLA-G.  The  correlation  between 
HLA-G expression and clinicopathologic features of 
NPC patients was analyzed by χ2 -test. For univariate 
survival analysis, survival curves were obtained using 
the Kaplan-Meier method.  In multivariate statistical 
analysis, we treated overall survival time as “time”, 
overall survival status as “status”, “death” as the ref-
erence  (with  a  value  of  1),  while  the  expression  of Int. J. Biol. Sci. 2012, 8 
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HLA-G  and  other  significant  clinicopathologic  fea-
tures (age, T classification, N classification, recurrence 
or metastasis and clinical stage) were treated as the 
comparing parameters (with a relative value), respec-
tively.  The  Cox  proportional  hazards  regression 
model was used to identify independent prognostic 
factors. Associations between the HLA-G expression 
and  IL-10  expression  or  number  of  CD68+  macro-
phages were examined by using Pearson correlation 
and independent t-test. Differences were considered 
significant if the P-value from a two-tailed test was 
less than 0.05. 
Results 
Patient characteristics 
Among the 552 patients, 418 (75.7%) were male, 
and  the  median  age  was  46  years  (ranging  19-78 
years).  Among  these  patients,  139  patients  (25.2%) 
were  diagnosed  as  non-keratinizing  differentiated 
carcinoma (NKDC), 400 patients (72.5%) were diag-
nosed  with  non-keratinizing  undifferentiated  carci-
noma (NKUC), and a few patients (0.3%) were diag-
nosed  with  keratinizing  squamous  cell  carcinoma 
(KSCC).  One  hundred  forty-seven  patients  (26.6%) 
were in stage I and stage II, and 405 patients (73.4 %) 
were in stage III and stage IV. The median follow-up 
time was 58.63 months (ranging 2 to 99 months). Of 
the total number of patients, 184 (33.3%) died and 217 
(39.3%) presented with disease progression during the 
five-year  follow-up  period.  Detailed  clinical  infor-
mation is shown in Table 1. 
Expression of HLA-G in NPC cell lines and 
tumor tissues 
To test the specificity of HLA-G antibody for the 
detection of HLA-G expression in NPC, western-blot 
assays were performed to evaluate the protein levels 
of HLA-G in the NPC cell lines including CNE2, S26, 
S18, SUNE1, 6-10B, 5-8F, CNE1, HONE1, C666 and an 
immortalized primary nasopharyngeal epithelial cell 
line  NP69.  Compared  to  non-tumorous  NP69  cells, 
NPC  cell-lines  expressed  higher  levels  of  HLA-G 
(Figure. 1A). Moreover, a single targeted band with 
clear background for each NPC sample indicates high 
specificity  of  the  antibody  against  HLA-G,  in  con-
sistent with manufacturer’s statement. 
 
 
 
Figure 1. Expressions of HLA-G in NPC cell lines and NPC tissues. A The HLA-G protein was visualized by western blot in the NPC cell 
lines CNE2, S26, S18, SUNE1, 5-8F, 6-10B, CNE1, HONE1, NP69 and C666 cells (molecular weight, HLA-G: 39KD, α-tubulin: 50 KD). B 
and C Weak HLA-G staining in TMA samples under low and high magnifications; D and E Strong HLA-G staining in TMA samples are 
shown under low and high magnifications; F, strong HLA-G staining in placenta tissue (positive control); G No HLA-G staining in normal 
nasopharyngeal epithelium tissue (negative control).  Int. J. Biol. Sci. 2012, 8 
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Figure 2. Selection of the cutoff score. Receiver operating characteristic curve analysis was employed to determine the cutoff score for 
the designation of “high expression” of HLA-G. The sensitivity and specificity for each outcome of HLA-G membranal and cytoplasmic 
staining were plotted: A T classification (P =0.431); B N classification (P =0.191); C Clinical stage (P =0.231); D Cancer progression (P 
<0.001); E Survival status (P <0.001).  
 
Subsequently, the expression of HLA-G protein 
was  determined  in  552  NPC  tumors  from  which 
five-year  follow-up  information  were  available,  by 
using  IHC  with  the  specific  antibody.  HLA-G  was 
detected  in  437  of  552  (79.2%)  NPC  cases.  Overex-
pression  of HLA-G  was observed in the  membrane 
and cytoplasm of NPC cells with different intensity 
(Figure 1B, C, D and E) and strong staining in placenta 
tissue  (positive  control)  (Figure  1F).  However,  no 
positive signal was observed in normal nasopharyn-
geal epithelium with this antibody (Figure 1G), indi-
cating again the specificity of the antibody and more 
importantly,  lack  of  HLA-G  expression  in  normal 
tissue. Immunoreactivity for HLA-G was scored for 
subsequent evaluation of its predictive value in NPC. 
Selection of the cutoff score for high expres-
sion of HLA-G  
ROC  curve  analysis  showed  that  HLA-G  ex-
pression  has  some sort  of predictive value in  NPC, 
with  maximum  area  under  curve  (AUC)  reaching 
0.640 (Figure. 2E, black arrowed). The points in curves 
with both maximum specificity and maximum sensi-
tivity  were  treated  as  cutoff  points  for  high  or  low 
expression of HLA-G. For survival analysis the cutoff 
score for the expression of HLA-G was 4.5 (Table 2). 
Thus, tumors designated as low expression of HLA-G 
are those with the scores below or equal to the cutoff 
score, while tumors of high expression are those with 
scores above the cutoff score.  
 
Table 2. The corresponding cutoff score of HLA-G ex-
pression for each clinicopathological feature according to 
ROC curve analysis 
Feature  Cutoff score   P value  
T classification  1.5  0.431 
N classification  5.5  0.191 
Clinical stage  1.5  0.231 
Cancer progression  4.5  <0.001 
Survival status   4.5  <0.001 
Note: HLA-G, human leukocyte antigen G; ROC, receiver operating 
characteristic. 
 
Association of HLA-G expression with clini-
copathologic features and survival  
As mentioned above and previously [28], sam-
ples were separated into either low or high HLA-G 
expression groups, according to their expression lev-
els  to  the  cutoff.  As  a  result,  high  expression  of 
HLA-G was observed in 187/552 (33.9%) of NPC tis-
sues.  With  χ2 -test  analysis,  we  found  that  high  ex-
pression  of  HLA-G  was  positively  correlated  with Int. J. Biol. Sci. 2012, 8 
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tumor N classification (Pearson Correlation = 0.120; 
P=0.005), recurrence or metastasis (Pearson Correla-
tion = 0.229; P<0.001) and histological type (Pearson 
Correlation  =0.166;  P<0.001),  respectively  (Table  3); 
while,  there  was  no  significant  association  between 
HLA-G  expression  and  other  clinicopathologic  fea-
tures, such as patient gender, age, tumor T classifica-
tion and clinical stage (P>0.05, Table 3).  
 
Table 3. Association of HLA-G expression and clinico-
pathological characteristics in NPC patients 
Characteristics  HLA-G IHC staining  P value 
low expression 
(N=365) 
high expression 
(N=187) 
Age, years      0.302 
<46  177  82   
>=46  188  105   
Gender      0.071 
Male  285  133   
Female  80  54   
Tumor stage      0.974 
T1+T2  143  73   
T3+T4  232  54   
Lymphoid Nodal(N)states    0.005 
N0  100  44   
N1-3  265  143   
Recurrence or metastasis    <0.001 
Yes  127  90   
No  238  97   
TNM clinical stage    0.807 
Ⅰ+Ⅱ  96  51   
Ⅲ+Ⅳ  269  136   
Histological type     <0.001 
NKUC  283  114   
NKDC  82  73   
Note: HLA-G, human leukocyte antigen G; ROC, receiver operating 
characteristic. 
 
 
The 5-year overall and disease-free survival rate 
of  the  cohort  of  552  NPC  patients  were  66.6%  and 
60.6%, respectively (Figure 3A and 3B). Of these 552 
NPC patients, Kaplan-Meier and  log-rank test anal-
yses  indicated  that  high  HLA-G  expression  signifi-
cantly  associated  with  poor  overall  survival  (OS) 
(5-year survival rates, 57.2% vs. 70.1%, log-rank test, 
X2  =  10.324,  P  =  0.001,  Figure  3C)  and  disease-free 
survival (DFS) (5-year survival rates, 51.9% vs. 64.8%, 
log-rank test, X2 =8.604, P = 0.003, Figure 3D) com-
pared with low HLA-G expression. When the clinical 
stages  were  taken  as  stratifications,  the  associations 
are  much  significantly  stronger  for  patients  at  late 
stages (stage III - IV), between HLA-G expression and 
poor  OS  (5-year  survival  rates,  42.6%  vs.  64.1%, 
log-rank  test,  X2  =  17.563,  P<0.001,  Figure  3G)  and 
DFS (5-year survival rates, 39.0% vs. 59.0%, log-rank 
test, X2 = 14.684, P<0.001, Figure 3H); while the asso-
ciations  are  not  significant  for  patients  at  the  early 
stages (stage I - II; Figure 3E and 3F). 
Independency test of the association between 
HLA-G expression and survival  
A univariate Cox proportional hazard regression 
analysis  showed  that  HLA-G  expression  (P<0.001), 
age  (P=0.002) and  the  well-known  clinicopathologic 
prognostic  parameters,  such  as  T  classification 
(P<0.001),  N  classification  (P=0.001),  recurrence  or 
metastasis (P<0.001) and clinical stage (P<0.001), were 
significantly  associated  with  survival  (Table  4). 
Moreover,  independency  tests  were  carried  out 
among the prognostic factors, including the expres-
sion  of  HLA-G  and  other  clinicopathologic  features 
(age,  T  classification,  N  classification,  recurrence  or 
metastasis  and  clinical  stage),  under  a  multivariate 
Cox proportional hazards regression model (Table 4). 
Compared  with  above  significant  clinicopathologic 
features (age, T classification, N classification, recur-
rence or metastasis and clinical stage), HLA-G was an 
independent  and  unfavorable  factor  for  overall  pa-
tient  survival  (hazards  ratio:  1.429;  95%  confidence 
interval:  1.050-1.945;  P=0.023).  Besides,  age,  recur-
rence  or  metastasis  and  clinical  stage,  respectively, 
were found to be independent prognostic predictors 
for overall survival (Table 4).  
Correlations of HLA-G expression and CD68+ 
macrophage and IL-10 in NPC tissue 
To elucidate the roles of HLA-G in immune reg-
ulation, we analyzed the correlation between expres-
sion of HLA-G and the number of CD68+ macrophage 
in tumor nest and stroma, which has been implicated 
in  tumor  microenvironment  [30].  Among  552  NPC 
tissues, HLA-G high expressions were inversely cor-
related  with  infiltrations  of  CD68+  macrophages  in 
tumor nest (19.53 ± 11.09/HPF vs, 21.89 ± 12.86/HPF 
Pearson  Correlation=-0.086;  P=0.025)  and  in  tumor 
stroma  (43.73  ±  22.11/HPF  vs,  50.66  ±  20.93/HPF 
Pearson  Correlation=-0.107;  P<0.001;  Figure  4),  re-
spectively, which is in consistent with previous report 
[13].  Moreover,  the  correlation  between  the  expres-
sion of HLA-G and IL-10 in the NPC samples were 
also examined, inspired by the previous demonstra-
tions that IL-10 as an important cytokine can induce 
HLA-G expression in other tumors [31]. The results 
showed a positive correlation between the expression 
of  HLA-G  and  IL-10  in  110  NPC  tissues  (Pearson Int. J. Biol. Sci. 2012, 8 
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Correlation=0.743;  P<0.001)  (Figure  5A).  For  the  52 
NPC cases with a high expression of HLA-G, the IL-10 
average  staining  score  was  5.67,  which  was  signifi-
cantly  higher  than  that  found  in  the  remaining  58 
NPC samples with low expression of HLA-G (3.90) 
(P<0.001, independent sample t-test; Figure 5B). 
 
Table 4 Univariate and multivariate Cox regression analyses of different prognostic variables in patients with NPC 
Variable  Subset  Hazard ration (95%) CI  P value 
Univariate analysis (N = 552)     
HLA-G IHC staining  low vs. high  1.629(1.217-2.180)  <0.001 
Age  <46 vs. >=46  1.613(1.198-2.172)  0.002 
Gender  male vs. female  0.835(0.587-1.190)  0.318 
T stage  T1+T2 vs. T3+T4  3.32(2.296-4.801)  <0.001 
N stage  N0 vs. N1+N2+N3  2.077(1.404-3.071)  0.001 
Recurrence or metastasis  No vs. Yes  606.868(84.874-4.339E3)  <0.001 
Histological type  NKUC vs. NKDC  1.179(0.894-1.554)  0.243 
Clinical stage  Ⅰ+Ⅱ vs. Ⅲ+Ⅳ  7.271(3.951-13.380)  <0.001 
Multivariate analysis (N = 552)     
HLA-G IHC staining  low vs. high  1.429 (1. 050 -1.945)  0.023 
Age  <46 vs. >=46  1.496 (1.098-2.039)  0.011 
T stage  T1+T2 vs. T3+T4  0.982 (0.622-1.551)  0.939 
N stage  N0 vs. N1+N2+N3  1.240 (0.822-21.871)  0.305 
Recurrence or metastasis  No vs. Yes  494.208 (68.913-3.54E3)  <0.001 
Clinical stage  Ⅰ+Ⅱ vs. Ⅲ+Ⅳ   2.471(1.184-5.159)  0.016 
Note: CI, confidence interval; WHO, World Health Organization; HLA-G, human leukocyte antigen G. 
 
 
 
Figure 3. Association between HLA-G expression and NPC patient survival. TMA analyses were conducted in a cohort of 552 NPC 
patients diagnosed at M0. A The five-year overall survival (OS) rate of was 66.6%. B The five-year disease-free survival (DFS) rate of was 
60.6%. C and D High HLA-G expression levels were significantly associated with OS (P = 0.001) and disease-free survival (P = 0.001) in all 
NPC patients. E and F No significant differences in five-year OS and DFS rates were found between groups with low and high expressions 
of HLA-G in NPC patients at early stages (I - II). G and H High HLA-G expression levels were significantly associated with OS (P = 0.006) 
and disease-free survival (P = 0.007) in NPC patients at late stages (Ⅲ-Ⅳ). Int. J. Biol. Sci. 2012, 8 
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Figure 4. Immunohistochemical staining of HLA-G expression and CD68+ macrophage. Representative pictures were shown. Weak 
HLA-G staining in tumor nest (A) and stroma (C) correlated with increasing infiltrations of CD68+ macrophages in tumor nest (B) and 
stroma (D); Strong HLA-G staining in tumor nest (E) and stroma (G) correlated with increasing infiltrations of CD68+ macrophages in 
tumor nest (F) and stroma (H); High expression of HLA-G significantly decreased infiltrations of CD68+macrophages in tumor nest (I) and 
tumor stroma (J) compared with low expression of HLA-G. 
 
 
 
 
Figure 5. IHC analysis showing correlation between the expression levels of HLA-G and IL-10 in NPC tissues. A Continuous sections of 
human NPC tissue were subjected to IHC staining with antibodies against HLA-G and IL-10. The tumor tissue in case 1 showed low 
expressions of HLA-G and IL-10; while the tumor tissue of case 2 showed the high expression levels of HLA-G and an elevated IL-10. B 
In 52 NPC cases with high expression levels of HLA-G, the average HLA-G score was 5.67 (right column), which was significantly higher 
than that (3.90) of the 58 NPCs with low expression levels of HLA-G (left column, P<0.001, independent sample t-test). 
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Discussion 
NPC is a malignancy arising at the upper lining 
of nasopharynx, and the strategies for early diagnosis 
and prognosis are keys for NPC survival. As  naso-
pharynx  is  an  important  lymphoid  tissue  [32],  im-
mune-related  genes  might  contribute  to  the  devel-
opment of NPC. Indeed, some immune-related genes 
especially the human leukocyte antigen (HLA) genes 
have been implicated in the NPC susceptibility [33]. It 
has  recently  been  reported  that  HLA-G  polymor-
phisms  are  associated  with  NPC  risk  and  clinical 
outcome [27]. However, to date, the expression and 
role of HLA-G in NPC have not been investigated.  
Here, we found that overexpression of HLA-G 
protein is likely correlated with NPC. The expression 
of HLA-G protein was higher in all the NPC cell lines 
tested, but low in the immortalized nasopharyngeal 
epithelial cell line NP69; and moreover, HLA-G pro-
tein  was  expressed  in  79.2%  of  552  NPC  patient 
specimens, but not in normal nasopharyngeal epithe-
lium tissue (Figure 1). These suggested that HLA-G 
might play an important role in the tumorigenesis of 
NPC.  Supportively,  the  overexpression  of  HLA-G 
antigens has been detected in various types of human 
malignancies, including gastric carcinoma [18], lym-
phoma  [19-20],  ovarian  [21]  and  endometrial  carci-
noma [22].  
The expression of HLA-G might contribute to the 
progression of NPC. Among the NPC patients, high 
expression of HLA-G was correlated with tumor N 
classification,  recurrence  and  metastasis  and  histo-
logical type, respectively (P<0.05, Table 3), which are 
well-known  factors  related  to  NPC  progression  as 
well as survival. Moreover, high expression of HLA-G 
was  correlated  with  poor  disease  free  and  overall 
survival rates of NPC. For patients at late stages, the 
strength of associations between high HLA-G expres-
sion  and  poor  survivals  is  much  enhanced.  These 
suggest that HLA-G might participate in the regula-
tion of NPC progression, and with more contribution 
in the advanced tumors. Importantly, the correlation 
of  HLA-G  expression  with  NPC  survival  and  the 
identification of HLA-G as an independent and un-
favorable  prognostic  factor  of  NPC  indicate  that 
HLA-G could be a useful biomarker for NPC progno-
sis. Further replication study using larger sample size 
might be necessary, before it’s applied to clinical us-
age.  
Considering the immunomodulatory function of 
HLA-G,  its  overexpression  in  malignant  cells  may 
represent one of various mechanisms adopted by the 
tumor  cells  to  escape  immune  surveillance  [31,  34]. 
Studies have shown that HLA-G expression can pro-
tect tumor cells from cytolysis mediated via natural 
killer cell (NK) and cytotoxic T lymphocyte (CTL) [35] 
and  block  the  effector  function  of  decidual  mono-
cyte/macrophages  [13].  To  better  understand  the 
possible role of HLA-G involved in NPC, we further 
determine  its  correlations  with  CD68+  macrophage 
and IL-10, which are also prognostic immune mole-
cules in NPC and play important role in the immune 
surveillance [30], [36-37]. We found a significant re-
verse  correlation  between  HLA-G  expression  and 
infiltrations of CD68+ macrophage in NPC tumor nest 
and tumor stroma tissues (Pearson Correlation=-0.086 
and  -0.107,  respectively).  It  has  been  shown  that 
CD68+ macrophage was able to secret tumor necrosis 
factor-alpha  and  killed  tumor  cells,  and  the  an-
ti-tumor  ability  was  promoted  when  it  was 
co-cultured with supernatant of NPC cells [30]. These 
results suggest a link between HLA-G and tumor as-
sociated macrophages regarding their regulatory roles 
in immune surveillance in NPC.  
On  the  other  hand,  we  found  that  IL-10  was 
highly expressed in NPC tissues, consistent with pre-
vious  reports  [36-37].  Moreover,  the  expression  of 
IL-10 was positively correlated with that of HLA-G in 
NPC  tissues.  Similarly,  the  expression  of  IL-10  has 
been  demonstrated  in  7  of  9  HLA-G  positive  cases 
with lung cancer [38]. These suggest a close functional 
relevance between IL-10 and HLA-G. As a supportive 
evidence, it has been found that IL-10 could induce 
HLA-G in human trophoblasts and mononuclear cells 
[15];  and  in  turn,  HLA-G  has  cytokine-regulating 
functions, which is associated with IL-10 expression in 
the evasion of immune surveillance [31]. Since IL-10 
has  anti-inflammatory  and  immunosuppressive  ac-
tivities, HLA-G might contribute to these processes, 
and interact with IL-10 during the malignant trans-
formation of NPC.  
In summary, we have demonstrated that HLA-G 
is  expressed  in  majority  of  NPC  samples;  and  that 
HLA-G  expression  is  a  strong  and  independent 
prognostic factor in NPC. Moreover, the correlations 
of HLA-G with other two prognostic factors, CD68+ 
macrophage and IL-10, were revealed in NPC tissues, 
suggesting that HLA-G might regulate the escape of 
tumor surveillance in the NPC. However, further in-
vestigations are necessary to reveal the precise func-
tion of HLA-G in NPC development.  
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